HRS9531 undergoes Phase 3 evaluation against Semaglutide for Type 2 Diabetes management

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to hyperglycemia. Despite existing therapies like metformin and SGLT2 inhibitors, many patients struggle to achieve adequate glycemic control, increasing risks of cardiovascular and renal complications. GLP-1 receptor agonists like semaglutide have shown significant efficacy in T2DM management, but there's a continuous need for novel agents that offer comparable or superior benefits, potentially with different safety profiles or administration advantages, to expand treatment options for diverse patient needs.

This Phase 3, randomized, open-label trial compares HRS9531 once weekly (QW) against Semaglutide QW. Participants with Type 2 Diabetes Mellitus inadequately controlled on metformin monotherapy or with SGLT2 inhibitors will receive either HRS9531 or Semaglutide. The study duration is 36 weeks for primary efficacy endpoints and 52 weeks for long-term safety. Key evaluations include efficacy (likely HbA1c reduction) and safety profiles of HRS9531 as an add-on therapy.